UAB Baltics medical

UAB Baltics medical We are a unique distribution company for innovative next generation medical devices in Baltic states.

Shockwave IVL - CoronaryProcedural success and safety advantages have been demonstrated in heavily calcified coronary ar...
28/08/2025

Shockwave IVL - Coronary
Procedural success and safety advantages have been demonstrated in heavily calcified coronary arteries using IVL.

𝗪𝗵𝗼 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗺𝗼𝘀𝘁?
Patients with moderate–severe coronary calcification where traditional balloon angioplasty risks inadequate lesion expansion or vessel injury.

IVL delivers controlled microfractures in calcific plaques at low pressure, enabling better stent delivery and expansion while minimizing trauma.

𝗗𝘂𝗿𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗺𝗮𝘁𝘁𝗲𝗿𝘀.
Currently, long-term patency and clinical outcome data for coronary IVL are pending or not sufficiently validated in RCTs; confidently including them would exceed confirmed data.

All major cath labs in Lithuania are equipped with Shockwave IVL for both peripheral and coronary applications.

Prep. Crack. Expand.

🔍 Has your lab integrated Shockwave IVL yet? We’d value hearing your perspective.

Shockwave IVL - Peripheral Procedural success 𝟲𝟱.𝟴% vs 𝟱𝟬.𝟰% with IVL vs PTA in calcified femoropopliteal lesions.Fewer ...
20/08/2025

Shockwave IVL - Peripheral
Procedural success 𝟲𝟱.𝟴% vs 𝟱𝟬.𝟰% with IVL vs PTA in calcified femoropopliteal lesions.
Fewer flow-limiting dissections 𝟭.𝟰% vs 𝟲.𝟴%.
Lower provisional stenting 𝟰.𝟲% vs 𝟭𝟴.𝟯%.

𝗪𝗵𝗼 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗺𝗼𝘀𝘁?
Patients with moderate–severe femoropopliteal calcification where PTA alone risks dissection or inadequate expansion—especially before DCB or stenting.

IVL fractures intimal and medial calcium at low pressure, enabling safe and controlled vessel preparation.

𝗗𝘂𝗿𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗺𝗮𝘁𝘁𝗲𝗿𝘀.
At 1 year, IVL maintained superior primary patency (80.5% vs 68.0%), confirming long-term vessel prep in complex PAD.

All major cath labs in Lithuania are equipped with Shockwave IVL.

Prep. Crack. Expand.

🔍 Has your lab integrated Shockwave IVL yet? We’d value hearing your perspective.

MANTA® by Teleflex is the large-bore femoral closure device built specifically for 12–25 Fr access so teams can close fa...
14/08/2025

MANTA® by Teleflex is the large-bore femoral closure device built specifically for 12–25 Fr access so teams can close fast, walk sooner, and keep labs moving.

Purpose-built design: a resorbable intra-arterial toggle and extravascular bovine collagen plug, plus a dedicated depth locator for accurate placement.

Single-device, simple deployment—no pre-closure sutures. Available in 14 Fr and 18 Fr sizes to cover your TAVR/TEVAR/EVAR workflow.

Proven speed: median time-to-hemostasis ≈ 24 seconds in SAFE-MANTA, far shorter than published suture-based times. Real-world series show rapid, effective closure with good safety.

Resorbable by design: the polymer toggle and collagen plug are absorbed over months—nothing permanent left behind at the arteriotomy.

Close. Ambulate. Discharge.

Freesolve by BIOTRONIK is a resorbable magnesium scaffold for de novo coronary lesions that delivers like a DES and is >...
12/08/2025

Freesolve by BIOTRONIK is a resorbable magnesium scaffold for de novo coronary lesions that delivers like a DES and is >99% resorbed at 12 months. CE-marked in Europe, with 3-year BIOMAG-I data showing 3.5% TLF and no MI, cardiac death, or scaffold thrombosis.

Who benefits most?
• Patients with de novo lesions in vessels sized to the platform (≈2.5–4.2 mm RVD), where precise sizing and standard pre/post-dilatation can be achieved.

• Younger patients with long life expectancy or those who prefer to avoid a permanent metal implant to preserve vasomotion, future imaging, and surgical options.

• Cases where future side-branch access and vessel physiology matter after healing; OCT data show 99.3% strut resorption at 12 months, supporting restoration of vessel function.

Why it’s compelling now
Magnesium backbone fully resorbed ≈12 months.
Metal-like support when needed; nothing left to trigger very-late events.
Stable outcomes to 3 years with no new events beyond year two.

Select carefully. Size precisely. Leave nothing behind.

iNstroke 4F by iVascular is a next-generation aspiration catheter engineered for rapid, high-flow distal clot removal in...
07/08/2025

iNstroke 4F by iVascular is a next-generation aspiration catheter engineered for rapid, high-flow distal clot removal in acute stroke.

With a true 0.040″ lumen and 155 cm working length, it delivers uncompromised aspiration deep into M3/M4 segments.

Hydrax Plus hydrophilic coating over 100 cm and eight graded stiffness zones ensure smooth, controlled navigation through tortuous neuro-vasculature.

Its nitinol coil and stainless-steel braid reinforcement prevent kinking under sustained suction, while the C-Cut radiopaque marker guarantees precise tip visibility.

Fast tracking. Powerful aspiration. Better outcomes.

Navitian by iVascular is the coronary microcatheter built to reach lesions other catheters can’t. A conical 1.8 F tip wi...
29/07/2025

Navitian by iVascular is the coronary microcatheter built to reach lesions other catheters can’t.

A conical 1.8 F tip with double C-cut radiopaque markers and 70–90 cm of Hydrax Plus hydrophilic coating slices through tight, tortuous arteries while keeping every move visible.

A full-length variable braided pattern and internal PTFE liner deliver the balance of pushability, flexibility, and kink resistance you need for precise guide-wire control deep inside the vessel.

Over-the-wire, 0.014″ compatible, and available in 135 cm and 150 cm working lengths with a 2.5 F proximal profile-ready for complex CTO work through a 4 F radial approach.

Navigate. Cross. Deliver.

Freesolve - BIOTRONIK’s third-generation resorbable magnesium scaffold (RMS) - just met the 3-year mark in the BIOMAG-I ...
25/07/2025

Freesolve - BIOTRONIK’s third-generation resorbable magnesium scaffold (RMS) - just met the 3-year mark in the BIOMAG-I first-in-human study.
Target-lesion failure holds at 3.5 % with no myocardial infarction, cardiac death, or scaffold thrombosis and no new events between years 2 and 3.

At 12 months the scaffold was 99.3 % resorbed, late-lumen loss averaged 0.24 mm, and TLF sat at 2.6 %, again with zero thrombotic or fatal events.

Metal-like radial support when you need it; nothing left behind when healing is done. A true alternative to permanent drug-eluting stents.

Baltics Medical is ready to bring innovative technologies to cath labs across Lithuania, Latvia and Estonia.

Metallic performance. Fully resorbable.

Nearly 3 000 coronary stents per million Europeans vs. ≈1 165 per million in middle-income countries worldwide. Latest E...
22/07/2025

Nearly 3 000 coronary stents per million Europeans vs. ≈1 165 per million in middle-income countries worldwide.

Latest EU Society of Cardiology numbers translate to roughly 2.2 million stents each year across Europe, while most of the rest of the world still averages fewer than half that rate evidence of a persistent access gap in cath-lab capacity and device availability.

Why it matters?

Scale: Europe has turned rapid PCI into the norm; middle-income regions are still catching up.
Outcome: Timely stenting shrinks infarct size, cuts complications, and gets patients home sooner.

Momentum: Countries like France (≈4 075 stents/million) show how high-volume practice and modern DES technology drive superior outcomes.

Our goal at Baltics Medical is to keep Europe’s momentum rolling eastward—delivering next-generation drug-eluting stents and on-demand clinical support so no Baltic patient waits for life-saving technology.

How many coronary stents did your centre place last year? Drop your number below let’s map Europe vs. the world together.

iCover® by iVascular is a balloon-expandable covered stent engineered for high precision, visibility, and post-expansion...
16/07/2025

iCover® by iVascular is a balloon-expandable covered stent engineered for high precision, visibility, and post-expansion performance in complex peripheral artery disease cases.

With radiopaque markers and a low-profile delivery system, iCover® offers unique visibility and smooth implantation, even in challenging anatomies.

Its cobalt-chromium platform and ePTFE covering provide strong radial force and reliable sealing, while its best-in-class post-expansion capacity (≥2mm) gives physicians the flexibility to adapt during procedures.

Outstanding flexibility. Small profiles. Proven performance.

iNtercept by iVascular is a self-expandable nitinol basket stent retriever engineered to restore blood flow quickly in a...
09/07/2025

iNtercept by iVascular is a self-expandable nitinol basket stent retriever engineered to restore blood flow quickly in acute ischaemic stroke.

Full-length visibility comes from a proximal gold marker, central gold markers arranged in a helical pattern, and distal platinum coils—so you always know where the device sits relative to the clot.

An axial slit and closed-cell architecture let the basket conform to the vessel wall and secure the thrombus during retrieval, while coil-reinforced tapered pushers keep pushability and torque control high all the way to the intracranial target.

Compatible with 0.017″, 0.021″, and 0.027″ microcatheters, iNtercept reaches vessels up to 5.5 mm without sacrificing trackability.

Retrieve. Reperfuse. Restore.

How TricValve® by P&F Products & Features GmbH Works Each TricValve® prosthesis couples a laser-cut nitinol frame with t...
03/07/2025

How TricValve® by P&F Products & Features GmbH Works

Each TricValve® prosthesis couples a laser-cut nitinol frame with three bovine-pericardium leaflets and a PTFE skirt for paravalvular-leak control.

Sizes cover SVC 25/29/33 mm and IVC 31/35/41/45 mm, matching caval diameters from 22 mm to 45 mm.

Both valves arrive pre-loaded on a single 28 Fr delivery catheter, no crimping, no rapid pacing.

Operators unsheath the SVC valve first, then position and deploy the IVC valve under combined fluoroscopic and echo guidance, securing a bicaval seal while sparing hepatic inflow.

Controlled delivery. Durable bicaval seal.

What TricValve® by P&F Products & Features GmbH Does Extreme-risk patients with severe tricuspid regurgitation often exp...
01/07/2025

What TricValve® by P&F Products & Features GmbH Does

Extreme-risk patients with severe tricuspid regurgitation often experience relentless caval reflux, ascites, and peripheral oedema because surgery is off the table.

TricValve® Transcatheter Bicaval Valve System changes that outlook by seating two self-expanding bioprosthetic valves, one in the superior vena cava (SVC) and one in the inferior vena cava (IVC), to block retrograde flow while leaving the native tricuspid untouched.

The transfemoral procedure typically takes about 30 minutes and requires only an 0.035″ stiff guidewire, offering rapid symptom relief and a short learning curve for implanters.

Early European experience shows fluoroscopy times around half an hour with > 95 % technical success.

Two valves. One procedure. Venous return restored.

Address

Subačiaus Gatvė 83-14
Vilnius
11342

Opening Hours

Monday 08:00 - 17:00
Tuesday 08:00 - 17:00
Wednesday 08:00 - 17:00
Thursday 08:00 - 17:00
Friday 08:00 - 17:00

Alerts

Be the first to know and let us send you an email when UAB Baltics medical posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram